Influence of TS (rs34743033) and RUNX1 (rs2014300) gene polymorphisms on survival outcomes of fluorouracil-based chemotherapy in Chinese advanced gastric cancer patients Rongbo Han,1â??3 Jingsun Wei,1 Honghong Zhang,1 Xinyu Su,1 Xia Chu,4 Yuetong Chen,1 Yang Gong,1 Xiujuan Wang,2 Junfeng Shi,1 Jinfei Chen1,5 1Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, Peopleâ??s Republic of China; 2Department of Oncology, Taixing Peopleâ??s Hospital, Taixing, Jiangsu,Peopleâ??s Republic of China; 3Clinical Research Center, Xuyi Peopleâ??s Hospital, Xuyi, Jiangsu, Peopleâ??s Republic of China; 4School of Medicine, Southeast University, Nanjing, Jiangsu, Peopleâ??s Republic of China; 5Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, Peopleâ??s Republic of China Background: This study aimed to explore the clinical correlation of single-nucleotide polymorphisms of thymidylate synthase (TS) and runt-related transcription factor 1 (RUNX1) in patients with postoperative stage II and III gastric cancer (GC).Patients and methods: Samples were obtained from 661 patients with postoperative stage II and III GC. TS (rs34743033) and RUNX1 (rs2014300) were genotyped in 261 patients who received postoperative basic platinum and fluorouracil chemotherapy regimens and 400 patients who did not accept chemotherapy. Results: TS (rs34743033) variant genotypes significantly prolonged the median overall survival (OS) time compared to the patients who only received adjuvant chemotherapy (HR 1.604, 95% CI 1.068â??2.410, p=0.021). Moreover, 3R/3R variant genotypes were demonstrated to have a positive effect on the OS of patients who received chemotherapy based on cisplatin (HR 1.754, 95% CI 1.041â??2.954, p=0.031) compared to oxaliplatin. A stratification analysis indicated that 2R/3R and 2R/2R variant genotypes were associated with inferior survival in GC patients with intestinal-type tumors, tumor less than 5 cm in size, and poorly differentiated tumors (p